Zealand Pharma major shareholder announcement: J O Hambro Capital Management
Company announcement – No. 4 / 2024
Zealand Pharma major shareholder announcement: J O Hambro Capital Management
Copenhagen, Denmark, 17 January 2024 – Zealand Pharma A/S (“Zealand”) (Nasdaq: ZEAL) (CVR-no. 20 04 50 78), a Copenhagen-based biotechnology company focused on the discovery and development of innovative peptide-based medicines, today announces the receipt on 17 January 2024 of notification pursuant to Section 38 of the Danish Capital Markets Act from J O Hambro Capital Management:
As of 11 January 2024, Perpetual Limited (the parent company of J O Hambro Capital Management) holds nominally 3,128,162 shares (each share carrying one vote) in Zealand Pharma A/S, corresponding to 5.004% of the total share capital and total voting rights in Zealand Pharma A/S.
Please see further details in the attached notification form.
# # #
About Zealand Pharma A/S
Zealand Pharma A/S (Nasdaq: ZEAL) ("Zealand") is a biotechnology company focused on the discovery and development of peptide-based medicines. More than 10 drug candidates invented by Zealand have advanced into clinical development, of which two have reached the market and three candidates are in late-stage development. The company has development partnerships with a number of blue-chip pharma companies as well as commercial partnerships for its marketed products.
Founded in 1998 and headquartered in Copenhagen, Denmark, Zealand has a team in the U.S. For more information about Zealand’s business and activities, please visit http://www.zealandpharma.com.
Contact:
Adam Lange (Investors)
Investor Relations Officer
Zealand Pharma
alange@zealandpharma.com
Anna Krassowska (Investors and Media)
Vice President, Investor Relations & Corporate Communications
Zealand Pharma
akrassowska@zealandpharma.com
Attachment
Legal Disclaimer:
EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.
